Amgen Inc. has recently unveiled significant advancements in their scientific research, highlighting their pioneering work in modular therapeutic design. Drawing inspiration from nature, Amgen is developing innovative treatments such as bispecific T-cell engagers and RNA-directed therapies. These novel approaches aim to understand biological complexity and create therapeutics with unprecedented impact for patients suffering from serious diseases. Additionally, Amgen is leveraging artificial intelligence and machine learning to accelerate drug discovery and development, selecting clinical trial sites and participants more efficiently, and expediting the regulatory review process. By utilizing vast human datasets, Amgen is also gaining genetic insights to develop precision medicines targeted at serious diseases, marking a pivotal moment for practicing precision medicine.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。